Effectiveness of acetylcholinesterase inhibitors: Diagnosis and severity as predictors of response in routine practice

International Journal of Geriatric Psychiatry

Volumn 21, Issue 8, 2006, Pages 755-760

  Van Der Putt, Rohan ^a   Dineen, Catherine ^a   Janes, David ^a   Series, Hugh ^a   McShane, Rupert ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Dementia; Predictors; Response

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFORMATION PROCESSING; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PREDICTION; PRESCRIPTION; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COHORT STUDIES; DEMENTIA; FEMALE; GREAT BRITAIN; HUMANS; LEWY BODY DISEASE; MALE; MENTAL STATUS SCHEDULE; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 33748333242     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1557     Document Type: Article

References (13)

1. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518.
2. European Medicines Evaluation Agency. 2006. Post authorisation summary of opinion for Exelon. http://www.emea.eu.int/pdfs/human/opinion/ 3171806en.pdf.
3. McKeith I, Del Ser T, Spano P, et al. 2000. Efficacy of Rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
4. National Institute for Clinical Excellence. 2001. Guidance on the use of Donepezil, Rivastigmine, and Galantamine for the treatment of Alzheimer's disease. Technology Appraisal Guidance-No. 19. http://www.nice.org.uk/pdf/ALZHEIMER_full_guidance.pdf.
5. National Institute for Health and Clinical Excellence. January 2006. Appraisal Consultation Document: Donepezil, Galantamine and Rivastigmine (review) and Memantine for the treatment of Alzheimer's disease. http://www.nice.org.uk.
6. Neary D, Snowden JS, Mann DMA, et al. 1986. Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry 49: 229-237.
7. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. 2003. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine use in Newcastle. Int J Geriatr Psychiatry 18: 879-886.
8. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2: 1457-1459.
9. Perry EK, Haroutunian V, Davis KL, et al. 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5: 747-749.
10. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. 2005. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 61: 361-368.
11. Royal College of Psychiatrists. 2005. Submission on behalf of the Royal College of psychiatrists by the Faculty of Old Age Psychiatry to the National Institute for Clinical Excellence. Health Techology Appraisal: Drugs for the treatment of Alzheimer's disease. www.rcpsych.ac.uk/ college/faculty/oap/members/NICESubr̄ch05.pdf.
12. Thomas AJ, Burn DJ, Rowan EN, et al. 2005. A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies. Int J Geriatr Psychiatry 20(10): 938-944.
13. Wallin A, Andreasen N, Eriksson S, Wattmo C, Minthon L. 2005. Analysis of the heterogeneity in treatment response to donepezil in Alzheimer's disease; conclusions from the Swedish Alzheimer Treatment Study Group P2:111. Int Psychogeriatr 17 (Suppl. 2): 315.